AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution

Amy E. Schade(Brigham and Women's Hospital), Karen Cichowski(Brigham and Women's Hospital), Kristian Helin(University of Copenhagen), Van T.M. Nguyen(Institute of Cancer Research), Kaia Mattioli(Brigham and Women's Hospital), Naiara Perurena(Brigham and Women's Hospital), Ana C. Garrido-Castro(Dana-Farber Cancer Institute), Natalie F. Pilla(Brigham and Women's Hospital), Alycia Gardner(Brigham and Women's Hospital), Marina Watanabe(Brigham and Women's Hospital), Patrick Loi(Brigham and Women's Hospital), Jason J. Zoeller(Harvard University), Stefania Morganti(Broad Institute), Jia‐Ren Lin(Harvard University), David A. Barbie(Dana-Farber Cancer Institute), Peter K. Sorger(Harvard University Press), Keiichi Ota(Dana-Farber Cancer Institute), Sara M. Tolaney(Harvard University), Anjana Krishnan(Brigham and Women's Hospital), Zhe Li(Brigham and Women's Hospital), Carrie L. Rodriguez(Brigham and Women's Hospital), Dongxi Xiang(Brigham and Women's Hospital), Gerald M. Mastellone(Brigham and Women's Hospital), Yoona Yang(Lehigh University), Rachel A. Davis(Brigham and Women's Hospital), Yilin Xu(Brigham and Women's Hospital), Simon Knott(Cedars-Sinai Medical Center), Sandro Santagata(Harvard University)
Nature
October 9, 2024
Cited by 56


Related Papers